Can-Fite BioPharma announced that positive Phase 2a study results of Namodenoson, a drug for advanced pancreatic ductal adenocarcinoma, have been accepted for presentation at the ESMO Congress 2026. The study showed durable disease stabilization and encouraging survival in patients who had progressed after standard therapies, with one second-line patient alive over 18 months. Namodenoson, targeting the A3 adenosine receptor, has a strong safety profile and is being further developed in combination with chemotherapy in a planned Phase 2b trial. This recognition at a leading oncology conference supports continued development of Namodenoson for this hard-to-treat cancer.
New data from BrightEdge reveals Google AI frequently uses Facebook and Instagram content to answer about 19.5 million consumer questions monthly, especially on local businesses, events, and culture. Facebook is the top source for timely, practical i...
Construction activity in Manitoba is forecast to increase through 2035, with strong growth in non-residential projects such as engineering, industrial, commercial, and institutional buildings. Residential construction will see modest growth, supporte...
The global urology devices market, valued at $39.23 billion in 2025, is projected to grow at a CAGR of 7.35% to reach $80 billion by 2035. Growth is fueled by rising demand for robotic-assisted surgeries, kidney disease management, and minimally inva...
The global quantum photonics market, valued at $0.77 billion in 2025, is projected to grow at a CAGR of 33.79% to reach $14.12 billion by 2035. Growth is fueled by the commercialization of quantum computing, secure quantum communication networks, and...
Patagonia Gold Corp. announced the passing of its former Chairman, Carlos J. Miguens, on July 18, 2026. Miguens played a vital role in the company's growth and was instrumental in advancing its flagship Calcatreu gold and silver project in Argentina....
